秋水仙碱在动脉粥样硬化性心血管疾病中的应用
炎症在动脉粥样硬化性血管疾病中起直接作用,口服秋水仙碱具有广泛抗炎特性。多项大型随机对照试验的荟萃分析显示,秋水仙碱可降低复发性主要不良心血管事件(MACE)风险25%,但未显示生存获益,且非心血管死亡风险有边缘性非显著增加38%。关键人群如心衰、血运重建术后、女性、老年人和非白种人在已完成试验中代表性不足,限制了普遍性。
要点
- 秋水仙碱降低复发性MACE风险25%,获FDA批准用于心血管疾病治疗和预防。
- 未显示生存获益,心血管死亡非显著降低18%,非心血管死亡边缘性非显著增加38%。
- 心衰、血运重建术后、女性、老年人和非白种人代表性不足,普遍性受限。
核心结论
- 秋水仙碱在降低MACE方面显示前景,但其净风险-获益特征需进一步阐明,才能在动脉粥样硬化性心血管疾病二级预防中广泛采用。
研究设计与样本
- 多项大型随机对照试验的荟萃分析,评估秋水仙碱对心血管结局的影响。
主要发现
- 秋水仙碱降低复发性MACE风险25%。
- 秋水仙碱未显示生存获益。
- 心血管死亡非显著降低18%(95% CI:降低45%至增加23%)。
- 非心血管死亡边缘性非显著增加38%(95% CI:降低1%至增加92%)。
关键数值与推荐
- C反应蛋白被提议作为秋水仙碱反应的生物标志物,有望识别高危人群,但尚待正在进行的随机对照试验验证。
临床怎么用
- 秋水仙碱已获FDA批准用于心血管疾病治疗和预防,但在动脉粥样硬化性心血管疾病二级预防中广泛采用前需进一步阐明净风险-获益特征。
局限性
- 心衰、血运重建术后、女性、老年人和非白种人等关键人群在已完成试验中代表性不足,限制普遍性。
- 仍需更多大规模、长期试验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammation has a direct role in the development of atherosclerotic vascular disease, and oral colchicine displays broad anti-inflammatory properties. Several large, randomised controlled trials (RCTs) have evaluated colchicine's impact on cardiovascular outcomes. Results from a meta-analysis of these trials demonstrate that colchicine reduces the risk of recurrent major adverse cardiovascular events (MACEs) by 25%, leading to its recent approval by the Food and Drug Administration for the treatment and prevention of cardiovascular disease. Despite this, colchicine has not been shown to confer any survival benefit in these trials. The non-significant reduction in cardiovascular death of 18% (95% CI: 45% decrease to 23% increase) is outweighed by a more prominent, borderline non-significant increase in the risk of non-cardiovascular death by 38% (95% CI: 1% decrease to 92% increase). Key populations including those with heart failure, those undergoing surgical revascularisation, women, elderly individuals and non-Caucasians are under-represented in completed trials, which limits generalisability. C reactive protein has been proposed as a biomarker for colchicine response and shows promise for identifying a high-risk population where the benefit on MACE reduction and specifically reduced cardiovascular death might outweigh any real increased risk of non-cardiovascular death; however, this approach is still to be validated in ongoing RCTs. In conclusion, while colchicine shows promise in reducing MACE, its net risk-benefit profile requires further elucidation before its widespread adoption into clinical practice for the secondary prevention of atherosclerotic cardiovascular disease. Much more large-scale, long-term trial data are still needed in this space.
引用
- Tucker, Goonetilleke, Patel, et al. Colchicine in atherosclerotic cardiovascular disease. Heart. 2024. PMID: 38331560. doi:10.1136/heartjnl-2023-323177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。